Segment and Geographic Information

9 Months Ended

Sep. 30, 2011

Segment Reporting [Abstract]

Segment and Geographic Information

Segment and Geographic Information

The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace and manages its business and operations as one segment. Revenues reported to date are derived primarily from the sales of Angiomax in the United States.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates.

	Three Months Ended September 30,								Nine Months Ended September 30,
	2011				2010				2011				2010
	(in thousands)								(in thousands)
Net revenue:
United States	$	111,561	92.4	%	$	100,234	94.8	%	$	328,849	93.3	%	$	301,065	94.7	%
Europe	6,060		5.0	%	4,018		3.8	%	18,429		5.2	%	13,613		4.3	%
Rest of world	3,152		2.6	%	1,491		1.4	%	5,223		1.5	%	3,288		1.0	%
Total net revenue	$	120,773			$	105,743			$	352,501			$	317,966

	September 30, 2011				December 31, 2010
	(in thousands)
Long-lived assets:
United States	$	118,451	99.0	%	$	117,095	98.8	%
Europe	1,121		0.9	%	1,213		1.0	%
Rest of world	63		0.1	%	220		0.2	%
Total long-lived assets	$	119,635			$	118,528